Following is the unofficial transcript of a CNBC interview with Novo Nordisk A/S (NYSE:NVO) CEO Lars Fruergaard Jørgensen, Novo Nordisk A/S Global Drug Discovery SVP Karin Conde-Knap
Biogen Alzheimer’s drug Aduhelm is the first new treatment for dementia approved by the FDA in decades, and it’s started a war over the brain drug pipeline.